- VOLUNTEER OPPORTUNITIES - |
|
Become a Leader: Volunteer for MSHP |
|
The Michigan Society of Health-System Pharmacists (MSHP) relies on volunteers to help the organization meet its professional goals. Volunteers can serve as committee members, officers or members of the MSHP Board of Directors, or serve as delegates to the American Society of Health-System Pharmacists (ASHP) House of Delegates. Please note that you must be an MSHP/Michigan Pharmacists Association (MPA) member to volunteer for the following committees or groups. Volunteers are appointed by the MSHP president-elect in November and December for the following calendar year. Learn more and submit an application by clicking the form below. |
|
Volunteer Opportunities
-
MSHP Board of Directors
-
Regional Societies
- Michigan Delegates to the ASHP House of Delegates
-
MSHP Committees
- Ambulatory Care Committee
- Antimicrobial Stewardship Committee
- Educational Affairs Committee
- Membership Committee
- Organizational Affairs Committee
- Professional and Legal Affairs Committee
- Public Affairs Committee
- Publications Committee
- Residency Committee
- Transitions of Care Committee
|
|
|
Submit an Award Nomination for MSHP or MPA |
|
Make a nomination (you or one of your colleagues) for the Michigan Society of Health-System Pharmacists (MSHP) and the Michigan Pharmacists Association (MPA) awards. Nominate one of your colleagues for an award to recognize their professional accomplishments! MSHP nominations are due Sept. 1. To learn more about MSHP, please visit www.MichiganPharmacists.org/MSHP.
Award Nominations
Additional information and printable and electronic nomination forms are available online.
- MSHP Pharmacist of the Year
- Professional Practice Award
- President's Award
- Joseph A. Oddis Leadership Award
These awards are presented at the MSHP Annual Meeting during the Town Hall on Oct. 29, 2021.
MPA Awards: MPA is accepting nominations until Oct. 1 for the following awards:
- Pharmacist of the Year
- Bowl of Hygeia
- Executive Board Medal
- Excellence in Innovation
- Distinguished New Pharmacist Practitioner
- Fred W. Arnold Public Relations
- Fellow of MPA
These awards are presented at the Annual Banquet & Awards Ceremony during the MPA Annual Convention & Exposition the last weekend in February. Learn more here or fill out and submit the form at left.
|
|
|
Preparing for the 'Back Nine'!
By Jesse Shuster, Pharm.D., BCPS, transitions of care clinical pharmacy specialist, Harper Hutzel Hospital/Rehabilitation Institute of Michigan, Detroit
|
|
We are now at the second half of the year! For the first half, members of our board have discussed ways to embrace and adapt; now is the time to review and elevate. What changes have you encountered so far this year, and how have you adapted? It is a good time to review that and make adjustments for the second half of the year to either salvage or edify the progress you have made.
What about the changes around you or placed upon you? These are the tougher pills to swallow – is there a liquid or suspension available?
Upon reviewing the first part of the year, I find it important to evaluate what currently takes up my time and focus. I think I can speak for most of us by saying there is not much more that can be added to our already-full plates! So how do we embrace and adapt? One of my favorite speakers, Matthew Kelly, says, “Our lives change when our habits change.” What are my overall habits and how is that affecting my ability to adapt and embrace change? We have to evaluate what we are doing and what we can remove from our plates. To further delve into this, I wanted to review the Stephen Covey’s four-quadrant time management method. By looking at this, we see what changes can be made for us to embrace and adapt more smoothly.
|
|
If we focus on what we have in the lower two quadrants, we can find things to empty off our plates to adapt and embrace the changes before us. What can be delegated to a colleague or subordinate? What can be eliminated entirely because of its lack of importance? If we make some strides in these areas, we can open to embrace the changes before us more fully. |
|
Reference:
- Covey, S.R. The seven habits of highly effective people 1989 - Simon and Schuster - New York In-text: (Covey, 1989)
- Table taken from https://www.wikiwand.com/en/The_7_Habits_of_Highly_Effective_People
|
|
Developing a Meaningful Ambulatory Pharmacy Quality Metric Dashboard
By Nada Farhat, Pharm.D., BCPS, BCACP, clinical pharmacy specialist, Henry Ford Hospital, Detroit; and
Insaf Mohammad, Pharm.D., BCACP, clinical assistant professor/ambulatory care specialist, Wayne State University, Detroit
|
|
Ambulatory pharmacists provide care across a variety of chronic and acute disease states that impact quality measures linked to clinical, humanistic and economic outcomes. These measures provide a basis for ambulatory pharmacists to evaluate their service provision, describe the impact of their efforts and justify sustainability and/or expansion of services. Therefore, it is important to identify, measure and share quality and outcome metrics. Measuring performance is necessary for quality and performance improvement.1 Furthermore, methodically measuring comprehensive outcomes are important to ensuring quality care is furnished to patients.2 Quality metric dashboards can provide the ambulatory pharmacist, administrators and other team members a visual tool of collected data that monitors completion of activities, while allowing for identification of any quality issues that need to be acted on.3 In this article, we will describe some of the key steps to developing an ambulatory care pharmacy quality metric dashboard. Figure 1 summarizes these steps for reference.
Figure 1: Steps to Developing an Ambulatory Pharmacy Quality Metric Dashboard
|
|
Step 1: Identify Relevant Metrics
A standard does not exist for dashboard creation as the included metrics should be tailored to the services provided by the pharmacy team.3 Nevertheless, the included measures typically involve those pertaining to outcomes, efficiency, effectiveness/quality and safety.3 Ambulatory pharmacists can follow a few important steps to help determine the quality metrics important to their practice: 1
- Determine strategic priorities,
- Define key performance indicators, and
- Develop and discuss targets and goals with key team members.
The development and selection of quality and outcome metrics should focus on those that are meaningful, feasible and actionable. A variety of metrics have been developed for health systems, payers and consumers/patients. Examples of organizations that create healthcare performance metrics are the Agency for Healthcare Research and Quality (AHRQ), the National Quality Forum (NQF), the National Committee for Quality Assurance (NCQA), the Pharmacy Quality Alliance (PQA), the American Society of Health-System Pharmacists (ASHP) Accountability Measures Work Group and professional healthcare provider organizations.1 Table 1 provides examples of outcomes in the following categories for possible inclusion and measurement via a dashboard (including, but not limited to): clinical, financial, health care utilization, humanistic and productivity outcomes.
Table 1: Examples of Outcomes to Include in a Dashboard
|
|
Table 1 definitions: HgbA1c (hemoglobin A1c), BP (blood pressure), LDL (low-density lipoprotein), UACR (urine albumin-to-creatinine ratio), INR (international normalized ratio), HIV (human immunodeficiency virus), COPD (chronic obstructive pulmonary disease), DM (diabetes mellitus), PDCM (provider-delivered care management), BCBSM (Blue Cross Blue Shield of Michigan), HF (heart failure) |
|
In addition to the examples of outcomes provided in Table 1, other examples of items to consider, including on a dashboard, include the following:1
- Total patients in the clinic population receiving pharmacist care (can describe percentage of patients with common disease states of interest),
- Number of patients meeting the measure versus not meeting the measure,
- Percentage metric met versus target, and
- Definition of measures (definition of what it means to meet versus not meet the measure).
Step 2: Define Patient Population
To demonstrate pharmacist value, one must be able to accurately identify patients assigned to their service, which may be accomplished through “flagging” pharmacists in the electronic medical record. This will be required to determine baseline metrics and evaluate improvements over time. Furthermore, pharmacist value may be further amplified by using comparator groups (non-pharmacist patients) to identify key factors that may predict optimal health outcomes.
Step 3: Determine Significant Partners
Ambulatory pharmacists should identify relevant partners from information technology departments that may help them identify existing dashboard platforms to use a template for their own, or to guide creation of a new dashboard. Additionally, it is important to determine key stakeholders who may influence which metrics and outcomes will be most relevant. These stakeholders will vary depending on the institution and practice site, but may include the following:
- Medical/institutional leadership: executive level managers (“c-suite”), quality workgroup, physician leaders;
- Pharmacy personnel: supervisors, colleagues; and
- Interprofessional team: providers, nurses, medical assistants, support staff.
Step 4: Create and Develop Dashboard
After the key factors above are determined, the dashboard should be published and shared by the information technology department. Using the steps above should allow for meaningful implementation of a dashboard at a variety of practice sites. Lastly, one must continually assess for necessary changes and improvements, in addition to adjusting the dashboard based on payer or stakeholder needs.
|
|
Bempedoic Acid: Additional Therapy for Hyperlipidemia?
By Sarah Hasan, Pharm.D., MBA, PGY1 pharmacy practice resident, St. Joseph Mercy Hospital, Ann Arbor
|
|
Earlier this month, I started my cardiac intensive care unit (ICU)/cardiology rotation. On my first day during rounds, the medical team was discussing a patient admitted for a ST-segment elevation myocardial infarction (STEMI) who was on a high intensity statin and ezetimibe prior to arrival. Despite this, her low-density lipoproteins (LDL) levels were over 120 mg/dL. Additional lipid lowering therapy options were discussed, in which bempedoic acid was brought up. Prior to this point, I was only familiar with PCSK-9 inhibitors as an additional therapy option. Later that day, I looked further into bempedoic acid and its clinical trials, which show promising data.
Bempedoic acid (Nexletol®) is a novel, non-statin therapy that was approved about one year ago for hyperlipidemia management in patients with established atherosclerotic cardiovascular disease (ASCVD) and/or familial hypercholesterolemia on a maximally tolerated statin who require additional LDL-lowering therapy.1
Bempedoic acid’s mechanism of action is unique in that it inhibits adenosine triphosphate-citrate lyase (ACL). ACL is an enzyme that is upstream of HMG CoA reductase (the enzyme that is inhibited by statins) in the cholesterol synthesis pathway. Additionally, bempedoic acid is a prodrug that is activated by very long-chain acyl-coenzyme A synthetase-1 (ACSVL1), which is primarily expressed in the liver.1,2 Since ACSVL1 is not expressed in skeletal muscle, it is thought to not cause myalgias like statins.1
The CLEAR Harmony trial, published in 2019, assessed the efficacy and safety of bempedoic acid in patients with established ASCVD and/or familial hypercholesterolemia and LDL > 70 mg/dL on a maximally tolerated statin (with or without additional lipid lowering therapy).2 Patients were assigned in a 2:1 ratio to receive bempedoic acid 180 mg or placebo and followed for 52 weeks. A total of 3,395 patients were randomized, with 1,488 assigned to receive bempedoic acid and 742 assigned to receive placebo. The average baseline LDL was 130 +/- 30 mg/dL; 50 percent of patients were on a high-intensity statin, about 98 percent had ASCVD (the other 2 percent had heterozygous familial hypercholesterolemia), and about 7.6 percent of patients were on additional ezetimibe therapy. At week 12 of the study period, bempedoic acid reduced LDL levels by an average of 19.2 mg/dL. Compared to placebo, this was an 18.1 percent difference (95 percent CI –20.0 to –16.1; P<0.001). This effect on LDL was sustained through the 52-week study period. The rate of adverse effects were similar between the study groups, with the most commonly reported being upper respiratory tract infections, myalgias, arthralgias, nasopharyngitis and muscle spasms.
This data is very promising and provides a valid alternative treatment option for cholesterol management in patients with ASCVD and/or familial hypercholesterolemia who require further LDL lowering in addition to statin therapy. Although bempedoic acid was approved by the U.S. Food and Drug Administration (FDA) after the most recent update to the 2018 ACC/AHA/MS cholesterol management guidelines, it has already been included in the 2019 European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS) guidelines. In fact, an expert analysis article published the American College of Cardiology discussed the “promising results” of the clinical trials and the role of bempedoic acid in therapy.3 Interestingly, since our discussion during rounds on my first day of rotation, I realized many of my patients could potentially benefit from bempedoic acid therapy. It will be interesting to see more of its use in clinical practice in the next few years and its incorporation into future guidelines.
|
|
References:
- Official HCP Site: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). Official HCP Site | NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). https://www.nexletolhcp.com/. Accessed January 7, 2021.
-
Ray KK, Bays HE, Catapano Al, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032.
- Tibuakuu M, Blumenthal RS, Seth S Martin. Bempedoic Acid for LDL-C Lowering: What Do We Know? American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/08/10/08/21/bempedoic-acid-for-ldl-c-lowering. Published August 10, 2020. Accessed January 7, 2021.
|
|
Northern Michigan Society of Health-System Pharmacists Update
By Tammy Busch, Pharm.D., BCPS, Munson Healthcare OMH, Gaylord; northern region representative, MSHP
|
|
Happy Summer!
The Northern Michigan Society of Health-system Pharmacists (NMSHP) started the spring off in April with a one-hour continuing education presentation on "Pharmacological Pain Management," covering routes, classes, benefits and drawbacks of various therapies that exist for pain relief, presented by Kim Gerhardt, RPh, of MidMichigan Medical Center.
In May, four pharmacy graduate year one (PGY1) residents at Munson Healthcare Traverse City presented their research projects for a total of two hours of live continuing education credits. Carrie Berkompas, Pharm.D., presented “A Multimodal Approach to Targeting Chair Time in a Community Cancer Center Infusion Suite.” Bradley Withrich, Pharm.D., presented “An Analysis of Traumatic Brain Injury Management in a Community Hospital Setting.” “Evaluation of the Use of Dexmedetomidine for Benzodiazepine Refractory Alcohol Withdrawal” was presented by Danielle Bouza, Pharm.D., and, lastly, Kyle Neilly, Pharm.D., presented “Incidence of Nephrotoxicity and Clinical Failure in Patients with MRSA Bacteremia Receiving Trough-based Vancomycin Dosing Strategy.”
As usual, NMSHP breaks for the summer after the May meeting, as summer is far too short and extremely busy. In the fall, Nick Tourney, Pharm.D., BCIDP, will be conducting a Penicillin Allergy Assessment Skin Testing (PAAST) certificate program. More to come on that as the details solidify.
|
|
OFFICERS
PRESIDENT | Rebecca Maynard | (269) 341-7982 | Bronson Methodist Hospital, Kalamazoo
PRESIDENT-ELECT | Shawna Kraft | (734) 232-6667 | Michigan Medicine, Ann Arbor
IMMEDIATE PAST PRESIDENT | Curtis Smith | (517) 364-3579 | Sparrow Hospital and Ferris State University, Lansing
TREASURER | Stephen Smith | (313) 576-8809 | Karmanos Cancer Institute, Detroit
EXECUTIVE VICE PRESIDENT | Dianne Malburg | (517) 819-4810 | Michigan Society of Health-System Pharmacists, Lansing
DIRECTORS
Stacy Brousseau | (269) 341-7407 | Bronson Methodist Hospital, Kalamazoo
Nadia Haque | (313) 874-5022 | Genetech, Novi
Kyle Schmidt | (616) 685-6675 | Spectrum Health, Grand Rapids
Jesse Shuster | (313) 966-7811 | DMC Harper University Hospital, Detroit
REGIONAL SOCIETY REPRESENTATIVES
CENTRAL | Magaret Malovrh | (517) 364-2351 | Sparrow Hospital, Lansing
NORTHERN | Tammy Busch | (989) 731-2163 | Munson Healthcare, Gaylord
SOUTHEASTERN | Macey Williams | (734) 330-3038 | Beaumont Hospital, Royal Oak
WESTERN | Julie Schmidt | (269) 341-7999 | Bronson Methodist Hospital, Kalamazoo
MANAGING EDITOR | Mary Beth Wardell | (517) 377-0232 | Michigan Pharmacists Association, Lansing
|
|
The MSHP Monitor is a publication of the Michigan Society of Health-System Pharmacists, published as a service to its members.
Michigan Society of Health-System Pharmacists - An Affiliated Chapter of the American Society of Health-System Pharmacists and a Practice Section of the Michigan Pharmacists Association
|
|
|
|
|
|
|
